Global Myelodysplastic Syndrome Market 2015-2019

SKU ID :TNV-10278234 | Published Date: 20-Jan-2016 | No. of pages: 81
About Myelodysplastic Syndrome

Myelodysplastic syndrome is a group of hematologic disorders that arise in the bone marrow and spread into the blood. The syndrome is characterized by the inability of the hematopoietic cells produced in the bone marrow to attain maturity. Cytological dysplasia is a common feature of the syndrome, progressing to acute myeloid leukemia in about 30% of individuals with myelodysplastic syndrome. The disease is age-related, mostly affecting people aged 60 and above. Smoking, exposure to radiation, contact with chemicals such as benzene, genetic mutations, and chemotherapy can cause myelodysplastic syndrome.

Technavio’s analysts forecast the global myelodysplastic syndrome market to grow at a CAGR of 9.93% during the period 2015-2019.

Covered in this report
The report covers the present scenario and the growth prospects of the global myelodysplastic syndrome market for 2015-2019. To calculate the market size, we consider revenue generated from the sales of various drugs used for treating myelodysplastic syndrome.
The report describes the market by region:
• Americas: The US, Canada, Mexico, and Brazil
• EMEA: The UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
• APAC: Japan, China, Australia, Singapore, South Korea, and India

Technavio's report, Global Myelodysplastic Syndrome Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Celgene
• Novartis
• Otsuka

Other prominent vendors
• Acceleron Pharma
• Amgen
• Astellas
• Astex
• Actinium Pharmaceuticals
• Bellicum Pharmaceuticals
• BioLineRx
• Celator Pharmaceuticals
• Cornerstone Pharmaceuticals
• CTI BioPharma
• Eli Lilly
• Gamida Cell
• GlaxoSmithKline
• KaloBios Pharmaceuticals
• Kiadis Pharma
• Mirati Therapeutics
• Onconova Therapeutics
• Strategia Therapeutics
• Sumitomo Dainippon Pharma
• Sunesis Pharmaceuticals
• Targazyme
• TetraLogic Pharmaceuticals

Market driver
• Rise in aging population
• For a full, detailed list, view our report

Market challenge
• Use of off-label drugs
• For a full, detailed list, view our report

Market trend
• Rise in public awareness
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
  • PRICE
  • $2500
    $4000
    Buy Now

Our Clients